Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• ChouTYChiuCHLiLHMutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancerClin Cancer Res200511103750375715897572
   PubMed Web of Science ®Google Scholar
• MitsudomiTKosakaTEndohHMutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol200523112513252715738541
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• ParkKTanEHO’ByrneKAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialLancet Oncol201617557758927083334
   PubMed Web of Science ®Google Scholar
• SoriaJCFelipECoboMLUX-Lung 8 InvestigatorsAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol201516889790726156651
   PubMed Web of Science ®Google Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol2016913427071706
   PubMed Web of Science ®Google Scholar
• WangSTsuiSTLiuCSongYLiuDEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJ Hematol Oncol2016915927448564
   PubMed Web of Science ®Google Scholar
• KhozinSWeinstockCBlumenthalGMOsimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancerClin Cancer Res20172392131213527923840
   PubMedGoogle Scholar
• WangSSongYYanFLiuDMechanisms of resistance to third-generation EGFR tyrosine kinase inhibitorsFront Med201610438338827770386
   PubMed Web of Science ®Google Scholar
• MoriKKondoTKamiyamaYKanoYTominagaKPreventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancerCancer Chemother Pharmacol200351540340612687289
   PubMed Web of Science ®Google Scholar
• KonoTSatomiMChisatoNTopical application of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositisWorld J Oncol201016232235
   PubMedGoogle Scholar
• KaseYHayakawaTIshigeAAburadaMKomatsuYThe effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of ratsBiol Pharm Bull19972099549579331975
   PubMedGoogle Scholar
• KaseYHayakawaTAburadaMKomatsuYKamatakiTPreventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the ratJpn J Pharmacol19977544074139469647
   PubMedGoogle Scholar
• KaseYSaitohKIshigeAKomatsuYMechanisms by which Hange-shashin-to reduces prostaglandin E2 levelsBiol Pharm Bull19982112127712819881638
   PubMedGoogle Scholar
• KonoTKanekoAMatsumotoCMultitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytesIntegr Cancer Ther201413543544524501112
   PubMedGoogle Scholar
• LoganRMGibsonRJSonisSTKeefeDMNuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapyOral Oncol200743439540116979925
   PubMed Web of Science ®Google Scholar
• ArrietaOVega-GonzálezMTLópez-MacíasDRandomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patientsLung Cancer201588328228825882778
   PubMed Web of Science ®Google Scholar
• MeloskyBAndersonHBurkesRLPan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancerJ Clin Oncol201634881081526573073
   PubMed Web of Science ®Google Scholar
• HirshVManaging treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancerCurr Oncol201118312613821655159
   PubMed Web of Science ®Google Scholar
• HirshVBlaisNBurkesRVermaSCroitoruKManagement of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitorsCurr Oncol201421632933625489260
   PubMed Web of Science ®Google Scholar
• KatoTYoshiokaHOkamotoIAfatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3Cancer Sci201510691202121126094656
   PubMed Web of Science ®Google Scholar
• UribeJMGelbmannCMTraynor-KaplanAEBarrettKEEpidermal growth factor inhibits Ca (2+)-dependent Cl− transport in T84 human colonic epithelial cellsAm J Physiol19962713914922
   Google Scholar
• ShawATSolomonBTargeting anaplastic lymphoma kinase in lung cancerClin Cancer Res20111782081208621288922
   PubMed Web of Science ®Google Scholar
• DholariaBHammondWSherdersALouYEmerging therapeutic agents for lung cancerJ Hematol Oncol20169113827938382
   PubMed Web of Science ®Google Scholar
• KimDWMehraRTanDSWActivity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicenter, open-label, phase 1 trialLancet Oncol201617445246326973324
   PubMed Web of Science ®Google Scholar
• YamashitaTArakiKTomifujiMKamideDTanakaYShiotaniAA traditional Japanese medicine Hangeshashinto (TJ-14) alleviates chemoradiation induced mucositis and improves rates of treatment completionSupport Care Cancer2015231293524943276
   PubMedGoogle Scholar
• SamosornSTanwiratBMuhamadNAntibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking groupBioorg Med Chem200917113866387219419877
   PubMed Web of Science ®Google Scholar
• GrycováLDostálJMarekRQuaternary protoberberine alkaloidsPhytochemistry200768215017517109902
   PubMed Web of Science ®Google Scholar
• MeloskyBLeighlNBRothensteinJSanghaRStewartDPappKManagement of egfr tki-induced dermatologic adverse eventsCurr Oncol201522212313225908911
   PubMed Web of Science ®Google Scholar
• LacoutureMEKeefeDMSonisSA phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancerAnn Oncol20162791712171827287210
   PubMed Web of Science ®Google Scholar
• JatoiADakhilSRSloanJANorth Central Cancer Treatment GroupProphylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)Support Care Cancer201119101601160720820817
   PubMedGoogle Scholar